Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs

Bad blood brews some of the main players in the world of weight loss. Nouvo Nordsk, OzemPIC and Wegov, summarized its partnership with Hims & HERS Health Inc.

Bloomberg News stated that the sudden solution to partnership Monday, just two months after it was beaten. Novo claims that HIMS uses “deceptive marketing” to sell compound Smaglutide to sell its users, despite a recent campaign of federal organizers. In a post to X, Andrew Dodom, CEO of HIMS, wrote, “We are disappointed to see the Novo Nordisk administration mislead the audience. … We refuse to be strong gunmen by any anti -violation drug company that violates independent decisions of service providers and reduce the patient’s choice.”

We are disappointed to see the Novo Nordisk administration misled the audience.

In recent weeks, the Novo Nordisk team has increasingly pressed control of clinical standards and directing patients to Wegovy regardless of whether it is better clinically for patients. We refuse …

Andrewdum (Andrewdudum) June 23, 2025

The appearance of the poultryide and other effective weights in recent years has changed largely obesity medicine. But the growing demand, high -end rates (higher than $ 1,000 per month), and soon produced the initial shortage of these treatments a black and gray market. Some people have gone online to buy fake or fake GLP-1 medications (sometimes with serious results); Instead chose compound versions-custom installations, often much cheaper than Semaglutide and Tirzepatide created by specialized pharmacies.

For some time, GLP-1 drugs were in the mysterious terrain, legally. Pharmacies are allowed to make and sell complex medications under certain circumstances, including if standard versions are deficient. Healthcare companies have used a remote like HIMS this last justification for GLP-1 marketing on a large scale for the public.

It is not surprising that Novo Nordisk and other GLP-1 makers were not fans of this practice and filed many lawsuits against these pharmacies and the GLP-1 sellers. These lawsuits are still ongoing, but the broth train has already ended significantly.

In February 2025, the Food and Drug Administration stated that the shortage of the country in the most popular GLP-1 drugs had been resolved; The agency has also set the final dates through which the GLP-1 compound production should be stopped under this logical basis. The guaranteed industry tried to no avail to prevent this ruling. At least now, pharmacies and companies such as HIM are legally allowed to provide the complex GLP-1 for very specific reasons, such as personal doses or medically required formulations (for example, avoid components that may cause allergies).

In late April, companies jointly announced that the reduced sale of Wegov. But Novo claims that Hims was trading. In a statement issued on Monday, he claims that HIMS “failed to adhere to the law prohibiting the mass sales of complex drugs under the wrong” allocation “and publishes deceptive marketing that endangers the patient’s safety.”

Novo says it is still open to work with health care companies as long as she does not participate in “illegal double”, and has existing agreements with other companies, such as RO, to sell drugs. But the short -term repercussions do not look good for any previous partner; Novo and Hims witnessed the decrease in stock prices today after the announcement. Novo Nordsek has also been generally struggled in recent times, as she recently launched the CEO amid decrease in shares and fierce competition from others in the field of obesity.